We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

5 hedge funds and large institutions have $2.58M invested in Blueprint Medicines in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 344 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

99% less funds holding

Funds holding: 354 → 5 (-349)

99.54% less ownership

Funds ownership: 99.58% → 0.04% (-100%)

100% less capital invested

Capital invested by funds: $8.24B → $2.58M (-$8.24B)

100% less funds holding in top 10

Funds holding in top 10: 29 → 0 (-29)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 344

Holders
5
Holders Change
-349
Holders Change %
-98.59%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
-29
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
344
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IA
IFP Advisors
Florida
+$2.06K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$822M
2
BlackRock
BlackRock
New York
-$784M
3
PCM
Pentwater Capital Management
Florida
-$500M
4
State Street
State Street
Massachusetts
-$286M
5
UBS Group
UBS Group
Switzerland
-$278M
Name Holding Trade Value Shares
Change 		Change in
Stake
HI
301
Harbour Investments
Wisconsin
– -$25.6K -200 Closed
HT
302
Headlands Technologies
Illinois
– -$23.7K -185 Closed
TWD
303
True Wealth Design
Ohio
– -$23.6K -184 Closed
CIAM
304
Caitong International Asset Management
Hong Kong
– -$23.1K -180 Closed
Bessemer Group
305
Bessemer Group
New Jersey
– -$22K -174 Closed
S
306
SignatureFD
Georgia
– -$20.4K -159 Closed
GRP
307
Global Retirement Partners
California
– -$20.1K -157 Closed
SCM
308
Sterling Capital Management
North Carolina
– -$20.1K -157 Closed
UB
309
UMB Bank
Missouri
– -$17.3K -135 Closed
RA
310
Rise Advisors
New York
– -$17.2K -134 Closed
RIL
311
Rothschild Investment LLC
Illinois
– -$16.7K -130 Closed
AF
312
Advisornet Financial
Minnesota
– -$16.3K -127 Closed
AF
313
Allworth Financial
California
– -$15.5K -121 Closed
CA
314
Clearstead Advisors
Ohio
– -$15.5K -121 Closed
VCM
315
Versant Capital Management
Arizona
– -$13.2K -103 Closed
CT
316
Clearstead Trust
Maine
– -$12.9K -101 Closed
BCM
317
Boreal Capital Management
Florida
– -$12.8K -100 Closed
TCM
318
TD Capital Management
Tennessee
– -$12.8K -100 Closed
SAM
319
Smartleaf Asset Management
Massachusetts
– -$12K -94 Closed
ACM
320
Accent Capital Management
Ohio
– -$10.3K -80 Closed
FDCDDQ
321
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$10.3K -80 Closed
CFB
322
Cullen/Frost Bankers
Texas
– -$8.97K -70 Closed
AAP
323
Arax Advisory Partners
Colorado
– -$7.82K -61 Closed
Mitsubishi UFJ Asset Management
324
Mitsubishi UFJ Asset Management
Japan
– -$7.43K -58 Closed
PFBT
325
Parkside Financial Bank & Trust
Missouri
– -$6.54K -51 Closed
10 11 12
13
14

BPMC Hedge Fund Activity: Q3 2025 in Review

5 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2025, worth a combined $2.58M — down 100% from $8.24B a quarter earlier.

Sellers outnumbered buyers: 344 funds closed out of BPMC and 0 opened new positions — a net loss of 344 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was IFP Advisors, adding an estimated $2.06K. The largest seller was Vanguard Group, exiting entirely with an estimated $822M sold.

  • 5 institutional investors held Blueprint Medicines (BPMC) as of Q3 2025, down from 354 in Q2 2025.
  • Funds reported $2.58M of Blueprint Medicines stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Blueprint Medicines positions in Q3 2025 and 344 closed out, a net change of -344 holders.
  • The largest Blueprint Medicines buyer in Q3 2025 was IFP Advisors, an estimated $2.06K added.
  • The largest Blueprint Medicines seller in Q3 2025 was Vanguard Group, an estimated $822M sold.

Based on aggregated 13F filings for Q3 2025.